Arc Invest CEO Cassie Wood (CEO, photo), who is considered a representative player in investment in growth stocks, selected gene editing technology companies as growth stocks worthy of long-term investment. He pointed out ‘Crisper Therapeutics’ (CRSP), ‘Intellia Therapeutics’ (NTLA), and ‘Editas Medicine’ (EDIT) as stocks to pay attention to and said, “The market cap will grow to $1 trillion in the future.” emphasized.
In a recent interview with CNBC, CEO Wood said, “The current share price of gene editing technology companies can be disappointing, but I see it as a great opportunity to buy at a low price for long-term investors. there,” he said. CRISPR-Cas9 is a technology that can transform a trait by correcting the nucleotide sequence of DNA that contains genetic information about a specific trait with gene editing technology.
He said, “As Apple is an innovative company that has changed our lives, it is natural to have a market capitalization of 1 trillion to 2 trillion dollars, but even such Apple cannot cure human diseases. As a result, these companies will be able to earn exclusive patent rights in the medical industry in the future.”
CRISPR Therapeutics, Intellia Therapeutics, and Editas Medicine have a combined market capitalization of only $16 billion as of December. Even when the stock price soared, it was less than $40 billion. However, CEO Wood said, “These companies are going to reach a market cap of $1 trillion.”
These three companies are considered global top-tier groups because they have entered the clinical stage of the gene-editing treatment pipeline. However, investment risks are not without risk. Since gene editing technology itself is a path no one has taken, it inevitably comes with risks, and it is also uncertain whether future therapeutics can be commercialized. Since no gene-editing treatment has yet been approved for marketing, it may also be an issue whether regulatory agencies will approve it, including ethical issues.
The recent share price is in a bearish zone. CRISPR Therapeutics fell more than 50% this year, and EditasMedicin also fell about 60%. On the other hand, Intellia Therapeutics has jumped more than 100% since the beginning of the year.
Reporter Seol Ji-yeon sjy@hankyung.com
Big tech that falls even more during the Omicron phase… Reason for fear of rate hike
Fed Changes, Volatility Continues on Omicron… CP…
VN index 38.73p (2.61%…
Cassie Wood, who lost 13% this week alone: ”Price will quadruple over the next five years…
Musk, Tesla (NASDAQ:) to sell 10 trillion won more stock[JaegilCho’sglobal[조재길의글로벌
A bullish scenario for JP Morgan… Just one day…
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
